The Late-Stage Premium: How Big Pharma's Patent Cliff Is Reshaping Global Biotech Deal Dynamics
Key Insights
Global pharma M&A activity reached $106 billion in H1 2025, the most active period since 2019, driven by looming patent cliffs in the late 2020s.
GSK acquired NewValent (search) for $10.6 billion at a 40% premium, gaining two lung cancer (search) drugs under FDA review, reflecting the scarcity value of validated late-stage assets.
Korean biotech firms predominantly out-license at Phase 1, structurally missing late-stage premiums, while Chinese companies advance to Phase 3 using faster and cheaper clinical trials.
The global pharmaceutical industry is witnessing a dramatic shift in deal-making dynamics as big pharma pours unprecedented capital into validated late-stage oncology assets. In the first half of 2025 alone, global pharmaceutical and biotech mergers and acquisitions reached $106 billion (approximately 160 trillion won), marking the most active period since the pre-pandemic peak of 2019. In just the past month, investments in oncology drug assets by global big pharma have exceeded 20 trillion won.
The driving force behind this surge is the so-called patent cliff: the blockbuster products that have sustained major pharmaceutical companies' cash flows will see their patents begin to expire one after another in the late 2020s. With predetermined revenue holes on the horizon and insufficient time to develop new drugs from scratch, the fastest solution is acquiring assets with validated targets and near-term revenue potential.
GSK Leads the Charge with a 40% Premium
The most striking example is GlaxoSmithKline's $10.6 billion (about 14 trillion won) acquisition of NewValent (search), the largest acquisition GSK has undertaken in nearly a decade. The deal was executed at a 40% premium to NewValent's closing price just before the announcement. Through this transaction, GSK gains two lung cancer (search) drugs already under review by the U.S. Food and Drug Administration.
Industry observers note that the 40% premium is not viewed as market overheating, but rather as the price of "asset scarcity." Such validated late-stage assets are rare and command increasingly higher prices as the patent cliff approaches.
Next-Generation Technologies Attract Bold Bets
Beyond late-stage assets, big pharma is also placing bold bets on next-generation technologies that have demonstrated differentiated data for targets previously considered difficult to address. Johnson & Johnson acquired Firefly Bio (search) for $1 billion (about 1.5 trillion won), gaining a technology platform that selectively degrades the KRAS (search) protein, which is involved in cancer cell growth signals. KRAS has long been considered a difficult target, making the technology itself highly valued.
Roche has agreed to invest up to $3 billion (about 4 trillion won) in a co-development partnership with Nyliix (search), which possesses technology for degrading BTK (search), a protein that is a key target in blood cancer treatment. These deals reflect a broader trend: the era of "ADC FOMO," when companies raced to acquire even unproven antibody-drug conjugate candidates just two to three years ago, has come to an end. Capital is now flowing into assets with demonstrated validation.
The Korean Biotech Dilemma
For the Korean biotech sector, capturing this "late-stage premium" is structurally difficult. The prevailing business model for domestic biotech companies is to secure development funds by out-licensing technologies at an early clinical stage, rather than carrying assets through to late clinical phases themselves. While this mitigates development risk, it also makes it structurally difficult to secure negotiating power for assets in the late phases, when clinical data accumulates, the probability of approval rises sharply, and asset value increases dramatically.
Alteogen serves as a representative example. The company out-licensed its platform technology that changes the delivery method of antibody drugs to Merck (MSD) (search). The subcutaneous injection formulation of Keytruda using this technology was approved last year. Keytruda generates approximately 42 trillion won in annual sales, and the switch to a subcutaneous formulation is expected to open up new market value. However, according to Merck's disclosures, Alteogen's royalty is set at about 2% of net sales. While out-licensing reduces development risk, it significantly limits the rights to the increased product value that comes with approval and commercialization.
As of the end of last year, only 57 new drug pipelines in Korea were undergoing Phase 3 trials. The Ministry of Health and Welfare established a 150 billion won Phase 3 clinical trial fund this year after repeated cases in which cash-strapped companies failed to overcome the so-called "death valley" of Phase 3, forcing them to export their technology prematurely.
China's Speed Advantage Reshapes Global Competition
The contrast with China is stark. According to a McKinsey report released earlier this year, the time China takes from new drug discovery to submission of an Investigational New Drug application in the early stages is 50–70% faster than the global average. The pace of patient recruitment for clinical trials in China is 2 to 5 times faster than in the United States or Europe, based on late-phase clinical studies. As of 2023, 39% of all clinical trials worldwide were conducted in China.
Zhang Fengning, a partner in McKinsey's Greater China Life Sciences Practice, stated in a recent interview with a U.S. biotech media outlet: "Big pharma's licensing deals are underpinned by a belief in Chinese companies' speed and cost competitiveness—the ability to get in faster and cheaper." China's share of global technology deals jumped from 8% to 30% in just two years.
A CEO of a biotech firm commented on the resulting negotiation dynamics: "Chinese companies can accumulate late-phase data using their own funds and rapid clinical trials, then hold out by saying, 'If you don't accept this price, we'll make a deal elsewhere.' In contrast, Korean companies, which bring only early-stage assets to the table, find it difficult to take the lead in negotiations."
Korea's Eroding Clinical Trial Standing
This trend has begun to shake Korea's long-standing reputation as a clinical trials powerhouse. According to the Korea National Enterprise for Clinical Trials, Korea's share of global clinical trials fell from fourth place in 2023 to sixth place in 2024. Seoul, which held the top spot among global cities since 2017, was overtaken by Beijing and dropped to second place.
A professor at a university hospital clinical trial center in Seoul warned: "Global markets are increasingly skeptical about whether Korean companies and the industry environment are equipped to see clinical trials through to the end. With China, armed with overwhelming speed, rapidly emerging as an alternative, this trend is only intensifying."
A Shifting Evaluation Framework
As late-stage asset premiums grow, the criteria for evaluating new technology transfer markets are also changing. Investors are now asking not "How much did the company sell the asset for?" but "How far did the company carry the asset itself?" Industry insiders say that for Korean biotech to take the next leap, companies will need to prove their development capabilities by carrying assets through to higher-value stages, rather than settling for early technology transfer.
Even with capital, only a handful of Korean companies have seen a drug through to global commercialization. The complex insurance structures and hospital sales networks in the U.S. and Europe create high entry barriers, making it more rational for new entrants to license out to big pharma and earn royalties. Only a very small number—such as SK Biopharmaceuticals (search), which sells the epilepsy drug Cenobamate through its U.S. subsidiary, and Celltrion, which built a U.S. sales network for the biosimilar Zymfentra (search)—have reached direct commercialization. Even these required years of investment in establishing local subsidiaries and recruiting sales personnel. Thus, selling technology at an early stage is less a strategic choice and more a "forced decision."